1. Scrip
  2. >>Therapy Areas

J&J keeps Alzheimer's focus with Alector collaboration

 
• By Mandy Jackson

Johnson & Johnson entered into a research collaboration with Alector, one of the companies in its biotechnology startup incubator in Northern California, to identify a therapeutic candidate against an undisclosed Alzheimer's disease target.

Johnson & Johnson entered into a research collaboration with Alector, one of the companies in its biotechnology startup incubator in Northern California, to identify a therapeutic candidate against an undisclosed Alzheimer's disease target.

J&J has a long history in Alzheimer's drug development and is seeking alternative approaches to the difficult disease. Financial terms...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By Xu Hu

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.

Cidara’s Fortunes Improve Quickly With Non-Vaccine Flu-Prevention Data

 
• By Joseph Haas

Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.

Exelixis Positions Zanzalintinib For Post-Cabozantinib LOE Future

 
• By Alaric DeArment

The company announced positive Phase III data in previously treated colorectal cancer for zanzalintinib and it could see sales of more than $1bn in that indication.